




Department of Obstetrics and Gynaecology  
Queen Mary Hospital  
The University of Hong Kong



# Gynaecological Oncology

## Annual Report 2020



# Gynaecological Oncology

Department of Obstetrics and Gynaecology  
Queen Mary Hospital  
The University of Hong Kong

Annual Report 2020



**HKU  
Med**

LKS Faculty of Medicine  
Department of Obstetrics  
& Gynaecology  
香港大學婦產科學系

## Message from Division Head

The gynaecological oncology division of the Department of Obstetrics and Gynaecology, the University of Hong Kong, has been providing training and service in gynaecological oncology for over 50 years. Our unit is a tertiary referral center for both the private and public sectors in Hong Kong. We also accept referrals from the hospitals in Macau. Starting from December, 2020, Ms Wong, Yan Yan Priscilla had become our cancer case manager (CCM) to provide better care coordination between patients and doctors. With collaboration with other departments, our scope of services includes colposcopy, chemotherapy, radiotherapy, surgery and palliative care.

Our unit is a recognized training center for gynaecological oncology by the Hong Kong College of Obstetricians and Gynaecologists (HKCOG) and the Royal College of Obstetricians and Gynaecologists (RCOG). During January to June 2020, we had Dr. MC Chan with us for her first 6 months of subspecialist training in gynaecological oncology. Apart from training subspecialist fellow, we also provide gynaecological oncology training for basic and higher specialist trainees in Obstetrics and Gynaecology, not only from our unit but also other hospitals in Hong Kong.

In addition to clinical service and research activities, our division was also active in promoting women's health in Hong Kong by giving public talks and presentations in the Family Planning Association, radio and TV programmes.

I would like to take this opportunity to thank our team members and our collaborators for their contribution.



H.Y.S. Ngan

Tso Yin-Kai Professor

Head of Department

# Table of contents

I	Staff List	4
II	Laboratory	7
III	Inpatient & Outpatient Services	9
IV	Team Activities	10
V	Outpatient Statistics	11
VI	Colposcopy Services	12
VII	Cervical Malignancies	14
VIII	Uterine Malignancies	15
IX	Ovarian Malignancies	17
X	Gestational Trophoblastic Neoplasia	19
XI	Vulval, Vaginal and Fallopian Tube Cancers	20
XII	Multiple Primary Malignancies	21
XIII	Operations for Malignant/Pre-malignant Diseases	22
XIV	Chemotherapy	25
XV	Publications and Abstracts	27

# Staff List

## **Gynaecological Oncologists**

Professor Ngan Yuen Sheung Hextan, Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chan Kar Loen Karen, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Tse Ka Yu, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chu Man Yee Mandy, Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Dr. Ngu Siew Fei, Assistant Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

## ***Subspecialist Trainee***

Dr. Chan Man Chi, Associate Consultant, Department of Obstetrics and Gynaecology, Tuen Mun Hospital

## ***Specialist Gynaecologists***

Dr. Kwok Shuk Tak Gladys, Resident Specialist, Department of Obstetrics and Gynaecology, Queen Mary Hospital

## ***Residents***

Dr. Ho King Dat Stanton, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jan – 14 Feb 2020)

Dr. Lai Kit Yan Francesca, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Apr – 15 May 2020)

Dr. Lai Hei Tung Theodora, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Apr – 30 Jun 2020)

Dr. Ng Shu Man Carmen, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul – 30 Sep 2020)

Dr. Chan Hey Yin Aaron, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Oct – 31 Dec 2020)

## **Clinical Oncologists**

Dr. Yuen Kwok Keung, Chief of Service, Department of Clinical Oncology, Queen Mary Hospital

Dr. Siu Wai Kwan Steven, Consultant, Department of Clinical Oncology, Queen Mary Hospital

## **Pathologists**

Professor Leung Suet-yi, Head of Department, Department of Pathology, University of Hong Kong

Professor Cheung Nga Yin Annie, Professor, Department of Pathology, University of Hong Kong

Dr. Ip Pun Ching Philip, Associate Professor, Department of Pathology, Queen Mary Hospital

## **Consultant Colorectal Surgeon**

Professor Law Wai Lun, Professor, Department of Surgery, Queen Mary Hospital

Dr. Oswens Siu-Hung Lo, Consultant, Department of Surgery, Queen Mary Hospital

## **Consultant Urologist**

Dr. Tsu Hok Leung James, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

## **Consultant Plastic Surgeon**

Dr. Chow Ling Yu Velda, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

## **Consultant Medical Oncologist**

Professor Kwong Yok Lam, Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong

## **Consultant Radiologist**

Dr. Lam Poy Wing Tina, Chief of Service, Department of Radiology, Queen Mary Hospital

Dr. Lee Yuen Phin Elaine, Assistant Professor, Department of Radiology, University of Hong Kong

### **Consultant Anaesthesiologist**

Dr. Chee Yee Eot, Chief of Service, Department of Anaesthesiology, Queen Mary Hospital

### **Consultant Clinical Psychologist**

Dr. Lina Wu, Senior Clinical Psychologist, Department of Psychiatry, Queen Mary Hospital

### **Medical Social Workers**

Ms Au Suk Cheung Helen, Social Welfare Department

### **Nurse Specialist in Stoma Care**

Ms. Chan Lai Hung, Nursing Officer, Queen Mary Hospital

### **Oncology Case manager:**

Ms. Wong Yan Yan, Priscilla, Advanced Practice Nurse, Queen Mary Hospital

### **Cluster Rehabilitative Palliative Care Team**

Dr. Chan Kwok Ying, Consultant, Palliative Medicine Unit, Grantham Hospital

Dr. Li Cho Wing Bryan, Associate Consultant, Palliative Medicine Unit, Grantham Hospital

Ms. Chiu Ho Yan, Registered Nurse, Grantham Hospital

### **Clinical Research Team**

Ms Lau Suk Kwan Lesley, Research Co-ordinator

Dr. Wei Na Tina, Research Co-ordinator

# Laboratory

## Staff

Dr. Chan Wai David, Assistant Professor  
Dr. Chan Wai Sun, Post-doctoral Fellow  
Dr. Chan Yau Sang, Post-doctoral Fellow  
Dr. Yung Ming Ho Mingo, Post-doctoral Fellow  
Dr. Liu Si Stephanie, Research Officer  
Dr. Siu Kwan Yee Michelle, Research Officer  
Mr. Chan Chan Keung Milton, Technician  
Mr. Chen Fu Shun, Senior Research Assistant  
Dr. Chan Kin Tak, Research Assistant  
Ms. He Fang Fang, Research Assistant  
Miss Lui Tsz Yiu Esther, Research Assistant

## Services

Hormonal assay and assays for tumour markers

## Research tools

HPV detection and genotyping	
ELISA	Cell line and culture
Immunohistochemistry	Transfection study
In situ hybridization assay	RNAi study
DNA, RNA and protein extractions	CRISPR/Cas9 Gene Editing
Conventional PCR and RT-PCR	Clonogenic assay
Quantitative PCR	Cytotoxicity assay
Quantitative RT-PCR	Cell proliferation assay
RNA protection assay	DNA copy number variation analysis
Western blot	Protein co-immunoprecipitation
DNA methylation analysis	Gene cloning
DNA sequencing	In vivo animal study
Microarray analysis	Laser-captured microdissection
Hypoxia chamber	3D organoids assay
Flow cytometry	Omics analysis
Yeast two hybrid	Omental conditioned medium model



Fluorescent microscopy

Ex vivo omental-tumor model

Fluorescent stereomicroscopy

Li-Cor Odyssey CLx near-infrared fluorescence imaging system

Gel documentation system

Microplate reader

SpectraMax L Microplate Read

# **Inpatient Services**

## **Gynaecological oncology ward**

22 beds in the open ward

2 private beds

3 day beds

## **Ward Manager**

Ms. Hui Fung Ping, Susanna

## **Operating Theatre**

2 Full-day lists per week

## **Operating Theatre Manager**

Ms. Sylvia Wong

# **Outpatient Services**

Colposcopy Clinic	4 sessions per week
Chemotherapy Clinic	1 session per week
Cancer follow-up Clinic	1 session per week
Trophoblastic Clinic	1 session per week
Day Chemotherapy	5 days per week
Patient Group Meeting	withheld due to COVID
Palliative Medicine Clinic	1 session per week
Pre-admission Clinic	1 session per week

## **Clinic In-charge**

Ms. Chung Suk Man, Advanced Practice Nurse, S5, Queen Mary Hospital

# Team Activities

Grand Round (Led by Prof. Hextan Ngan)	1 per week
Discussion of New Cases and Treatment (Led by Prof. Hextan Ngan)	1 per week
Radiology Meeting (Led by Prof. Hextan Ngan and Dr. Elaine Lee)	1 per week
Chemotherapy Meeting (Led by Prof. Hextan Ngan)	1 per week
Morbidities and Mortality Meeting (Led by Prof. Hextan Ngan)	1 per week
Pre-operative Round (Led by Prof. Hextan Ngan)	1 per week
Tumour Board Meeting/Pathology Review (Led by Prof. Hextan Ngan and Prof. Annie Cheung)	1 per week
Laboratory Research Meeting (Led by Prof. Hextan Ngan)	1 per month
Clinical Research Meeting (Led by Prof. Hextan Ngan)	1 per 6 weeks

# Outpatient Statistics

## *Oncology Clinics Attendances*

	2016	2017	2018	2019	2020
Cancer Follow-up Clinic	4010	4183	4322	4207	<b>3918</b>
Trophoblastic Clinic	907	856	726	667	<b>531</b>
Chemotherapy Clinic	1894	1758	2044	2219	<b>2633</b>
Preadmission Clinic	-	-	95	174	<b>162</b>
Research Clinic				15	<b>0</b>

## *Patient Group Meeting*

### **Oncology patients support group which was led by:**

- Ms. Susanna Hui (Ward Manager)
- Ms. Tang Lai Chun (Advanced Practice Nurse)
- Ms. Cheng Sze Ki (Registered Nurse)

### **Stoma patients support group which was led by:**

- Ms. Susanna Hui (Ward Manager)
- Ms. Chan Lai Hung (Nursing Officer)

### **Oncology patient support group: withheld due to COVID**

Total no. of sessions: 0  
 Total no. of attendance: 0

### **Stoma patient support group: withheld due to COVID**

Total no. of sessions: 0  
 Total no. of attendance: 0

### **Annual patient group party: withheld due to COVID**

# Colposcopy Services

## *Colposcopy Clinics*

### **Queen Mary Hospital**

4 sessions - Monday afternoon, Tuesday morning, Thursday and Friday afternoon

## *Cervical Smear Clinics (run by nurses)*

### **Queen Mary Hospital**

3 session - Monday afternoon, Tuesday morning and Thursday afternoon

## **Statistics**

New Cases	493
Follow-up	1207


<b>Diagnosis (based on worst histology)</b>	<b>Cervix</b>	<b>Vagina</b>	<b>Vulva</b>
Normal	67	9	
Inflammation	31		
Warts/HPV	42	2	
Low grade squamous intraepithelial lesion	188	14	
High grade squamous intraepithelial lesion	61	8	
Microinvasive carcinoma			
Squamous cell carcinoma	2		
Adenocarcinoma	1		
Adenocarcinoma in-situ			
No histology	55	5	0
Unsatisfactory for assessment	7	2	
Others			
Atrophy	1	1	
Atypical cells	2		
Endocervical polyp	2		
Metastatic adenocarcinoma			
Paget's disease			
Recurrence of cervical cancer		1	
Recurrence of cancer of uterine corpus		1	

**Procedures**

Cone biopsy	0
Cryotherapy	0
Large loop excision of transformation zone	82
Under local anaesthesia	78
Under general / spinal anaesthesia	4


# Cervical Malignancies

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Number of New cases	98	62	83	84	82	87	101	73	84	91	<b>63</b>
Stage I	36	26	36	42	42	43	36	36	33	27	<b>21</b>
Stage II	35	27	22	21	19	17	26	18	24	23	<b>10</b>
Stage III	11	4	15	16	14	12	14	11	11	18	<b>17</b>
Stage IV	5	3	5	3	2	6	8	3	9	14	<b>8</b>
Unstaged	3	1	1	1	3	0	5	2	4	1	<b>0</b>
Recurrence	8	1	4	1	2	9	12	3	3	8	<b>7</b>



## 2020 New Case


Age	
≤ 30	3
31-40	14
41-50	10
51-60	22
61-70	10
71-80	2
> 80	2
<b>Total</b>	<b>63</b>



# Uterine Malignancies


## Carcinoma of Endometrium

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Number of New Cases	100	78	110	121	146	115	134	128	147	162	<b>149</b>
Stage I	64	45	64	70	83	69	88	81	88	106	<b>85</b>
Stage II	10	5	10	8	16	10	10	11	14	9	<b>8</b>
Stage III	15	16	23	25	26	18	23	24	26	24	<b>18</b>
Stage IV	4	5	4	5	12	7	9	6	13	12	<b>23</b>
Unstaged	6	4	7	10	8	7	2	3	5	2	<b>7</b>
Recurrence	1	3	2	3	1	4	2	3	1	9	<b>8</b>



## 2020 New Case

Age	Case Number
≤ 30	4
31-40	8
41-50	23
51-60	60
61-70	37
71-80	15
> 80	2
<b>Total</b>	<b>149</b>






## Other Uterine Malignancies

	2015	2016	2017	2018	2019	2020
Endometrial stromal sarcoma	3	5	3	8	3	4
Leiomyosarcoma	6	5	14	7	9	5
Malignant mixed mullerian tumor (MMMT)	5	8	11	8	8	8
Adenosarcoma	0	0	1	0	0	0
Chondrosarcoma	0	0	1	0	0	0
Rabdomyosarcoma	0	0	1	0	0	0
Smooth muscle tumour of undetermined malignant potential (STUMP)	1	3	0	1	3	2
Dedifferentiated endometrial carcinoma	0	0	1	0	0	0
Undifferentiated endometrial sarcoma	2	0	0	0	1	0
Uterine tumour resembling ovarian sex cord tumour	0	0	1	0	0	0
Uterine small cell carcinoma	0	1	0	1	0	0
Undifferentiated carcinoma sarcoma	0	1	1	4	0	0
						2
carcinomsarcoma						1

# Ovarian Malignancies


## Epithelial Ovarian Cancer

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Number of New cases	69	55	61	64	78	76	76	66	79	95	<b>51</b>
Stage I	21	22	26	30	25	22	32	14	27	40	<b>23</b>
Stage II	4	6	9	7	7	5	4	11	2	8	<b>3</b>
Stage III	13	21	16	16	32	33	16	22	14	25	<b>12</b>
Stage IV	15	6	4	10	9	10	13	12	14	15	<b>8</b>
Unstaged	7	0	2	1	1	1	2	1	1	0	<b>0</b>
Recurrence	9	0	4	0	4	5	9	6	21	7	<b>5</b>



## 2020 New Case

Age	
≤ 30	0
31-40	2
41-50	14
51-60	17
61-70	10
71-80	6
> 80	2
Total	51



### Ovarian Tumour of Low Malignant Potential

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Number of new cases	13	8	19	19	19	18	13	22	12	13	<b>22</b>
Stage I	11	7	15	14	15	16	6	19	10	12	<b>20</b>
Stage II	0	0	0	2	1	0	1	2	0	0	<b>0</b>
Stage III	1	0	2	2	2	2	1	0	1	1	<b>1</b>
Unstaged	0	0	0	1	0	0	0	0	0	0	<b>1</b>
Recurrence	1	1	2	0	1	0	4	1	0	0	<b>0</b>

### Germ Cell Tumour

2 patients had stage at least 1c immature teratoma.

1 patient had stage 1a mmature teratoma with yolk sac component.

### Sex Cord-Stromal Tumour

1 patient had stage 1a granulosa cell tumour.

1 patient had stage 1c2 granulosa cell tumour.

### Other Ovarian Malignancies

1 patient had stage 3 MMMT

1 patient had stage at least 1a mucinous carcinma associated with tiny component of mature teratoma.


1 patient had unstaged unknown ovarian malignancy

### Primary Peritoneal Carcinoma

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total	19	3	13	10	10	9	15	9	11	16	<b>10</b>
Stage II		0	2	0	0	0	1	0	0	0	<b>1</b>
Stage III		1	5	7	4	7	9	1	6	8	<b>4</b>
Stage IV		2	5	3	4	1	4	3	4	7	<b>4</b>
Unstaged		0	1	0	1	0	1	4	1	1	<b>1</b>
Recurrence		0	0	0	1	1	0	1	0	0	<b>0</b>


# Gestational Trophoblastic Neoplasia

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Number of New cases	15	10	21	16	17	14	12	10	12	10	<b>10</b>
Stage I	10	9	18	12	10	8	8	8	9	6	<b>8</b>
Stage II	1	1	0	0	1	0	0	0	1	0	<b>0</b>
Stage III	1	0	2	2	5	2	2	2	2	2	<b>2</b>
Stage IV	1	0	1	2	0	1	1	0	0	1	<b>0</b>
Unstaged	0	0	0	0	0	0	0	0	0	1	<b>0</b>
Recurrence	2	0	0	0	1	1	1	0	0	0	<b>0</b>



## 2020 New case

Age	
≤ 30	1
31-40	6
41-50	2
> 50	1
Total	10



# Vulval, Vaginal and Fallopian Tube Cancers

## Vulval Cancer

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Number of New Cases	11	5	8	7	9	6	6	9	12	1	13
Stage I	5	0	2	4	4	0	3	6	2	0	3
Stage II	0	0	1	0	0	1	0	0	4	0	0
Stage III	2	2	1	1	3	1	1	3	1	0	4
Stage IV	1	1	2	1	0	1	0	0	1	1	2
Unstaged	2	2	1	0	1	1	1	0	2	0	3
Recurrence	1	0	1	1	1	2	1	0	2	0	1

## Vaginal Cancer

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Number of New Cases	0	5	8	3	3	5	7	5	5	4	6
Stage I	0	0	2	0	1	0	0	0	0	0	0
Stage II	0	4	1	1	1	4	5	1	3	2	3
Stage III	0	1	1	0	0	0	0	1	2	0	0
Stage IV	0	0	2	2	0	1	1	2	0	0	3
Unstaged	0	0	1	0	0	0	0	0	0	1	0
Recurrence	0	0	1	0	1	0	1	1	0	1	0

## Fallopian Tube Cancer

Year	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Number of New Cases	0	0	1	0	3	2	5	4	2	1	7
Stage I	0	0	1	0	0	0	0	1	0	0	1
Stage II	0	0	0	0	0	0	1	2	0	0	1
Stage III	0	0	0	0	1	0	2	0	1	1	2
Stage IV	0	0	0	0	2	2	1	1	0	0	2
Unstaged	0	0	0	0	0	0	0	0	0	0	0
Recurrence	0	0	0	0	0	0	1	0	1	0	1

# Multiple Primary Malignancies

2020		Number	
Primary	Stage	Primary	Stage Number
Ca Corpus	1 +	Ca Ovary	1 2
Ca Corpus	1 +	Ca Ovary	2 2
Ca Corpus	1 +	Ca Ovary	3 2
Ca Corpus	1 +	Ca Ovary	4 1
Ca Corpus	1 +	Ca Lung	2 1
Ca Corpus	1 +	Ca Peritoneum	unstaged 1
Ca Corpus	2 +	Ca Ovary	2 2
Ca Corpus	3 +	Ca Ovary	1 2
Ca Corpus	3 +	Ca Ovary	unstaged 1
Ca Corpus	3 +	Ca Breast	3 1
Ca Corpus	4 +	Ca Ovary	3 1
Ca Corpus	unstaged +	Ca Bladder	unstaged 1
Ca Corpus	recurrence +	Ca Ovary	recurrence 2
Ca Ovary	1 +	Ca Breast	1 1

## Operation for Malignant/Pre-malignant Diseases

	<b>Number of procedures</b>
Laparotomy (all cases with open abdominal surgery)	109
Radical hysterectomy +/- unilateral / bilateral salpingo-oophorectomy (U/BSO)	5
Laparoscopic radical hysterectomy +/- U/BSO	4
Laparoscopic radical hysterectomy +/- U/BSO (Da Vinci)	4
Modified radical hysterectomy +/- U/BSO	5
Laparoscopic modified radical hysterectomy +/- U/BSO (Da Vinci)	5
Total abdominal hysterectomy +/- U/BSO	75
Total laparoscopic hysterectomy +/- U/BSO	53
Total laparoscopic hysterectomy +/- U/BSO (Da Vinci)	26
Laparoscopic radical trachelectomy	2
Laparoscopic radical trachelectomy (Da Vinci)	2
Pelvic lymphadenectomy (one side)	39
Laparoscopic pelvic lymphadenectomy (one side)	30
Laparoscopic pelvic lymphadenectomy (one side) (Da Vinci)	47
Paraaortic lymphadenectomy	32
Laparoscopic paraaortic lymphadenectomy	11
Laparoscopic paraaortic lymphadenectomy (Da Vinci)	28
Omentectomy	49
Laparoscopic omentectomy	9
Laparoscopic omentectomy (Da Vinci)	9
Adhesiolysis	12
Laparoscopic adhesiolysis	9
Laparoscopic adhesiolysis (Da Vinci)	5
BSO / USO / ovarian cystectomy	5

Laparoscopic BSO / USO / ovarian cystectomy	6
Laparoscopic BSO / USO / ovarian cystectomy (Da Vinci)	2
Appendicectomy	12
Laparoscopic appendicectomy	3
Laparoscopic appendicectomy (Da Vinci)	0
Debulking surgery	28
HIPEC	2
Bowel resection and re-anastomosis	6
Colostomy / ileostomy	5
Closure of stoma	0
Repair of bowel	2
Repair of bladder	0
Repair of vessels	0
Repair of vagina / perineum	2
Vault stripping / vaginectomy	5
Wide local excision of vulva	5
Radical vulvectomy	2
Groin node dissection (one side)	4
Cone biopsy	2
Large loop excision of transformation zone	2
Brachytherapy	24
Removal or insertion of central line insertion	4
Diagnostic hysteroscopy	3
Hysteroscopic polypectomy	0
Suction evacuation	0
Laparoscopic biopsy	7
Diagnostic laparoscopy	13
Examination under anaesthesia	6



Cystoscopy	1
Staging laparotomy	36
Lap myomectomy	2
Lap myomectomy (Da Vinci)	1
Biopsy of sentinel LN (Da Vinci)	7
Dilatation and curettage	23
Resection of fibroid	1
Biopsy of cervix	2
Local skin flap	1
Resuturing of post-operative abdominal wound	1
Colposcopy, Cervical biopsy, endocervical curettage, Diagnostic hysteroscopy, curettage	2

# Chemotherapy

Total number of patients receiving in-patient chemotherapy: 242

Total number of patients receiving out-patient chemotherapy: 277

Total number of patients receiving oral chemotherapy: 47

Total number of patients receiving PARP inhibitors: 43

Chemotherapy Regimen	Number of courses	
	In patient	Outpatient
Actinomycin D	6	7
Adriamycin	27	66
Adriamycin/Cisplatin	0	1
Adriamycin/Ifosmamide	1	0
Doxorubicin/Ifosfamide	3	0
Avelumab/Axitinib (clinical trial)	25	8
BEP (bleomycin, etoposide, cisplatin)	5	6
Bevacizumab	2	1
Carboplatin	4	21
Carboplatin/Etoposide	3	10
Carboplatin/Gemcitabine	6	34
Carboplatin/Gemcitabine/Bevacizumab	1	9
Carboplatin/Iriontecan	1	0
Carboplatin/Liposomal doxorubicin	6	6
Carboplatin/Paclitaxel	361	560
Carboplatin/Paclitaxel/Bevacizumab	21	33
Carboplatin/Taxotere/Bevacizumab	1	2
Cisplatin	16	54
Cisplatin/Etoposide	1	3
Cisplatin/Gemcitabine	2	11
Cisplatin/Gemcitabine/Bevacizumab	1	1
Cisplatin/Paclitaxel	10	0
Cisplatin/Paclitaxel/Bevacizumab	8	0
Cyclophosphamide (oral)	0	20
EMA-CO (etoposide, methotrexate and actinomycin D/ cyclophosphamide and vincristine)	15	0
Gemcitabine	35	106
Gemcitabine/Taxotere	0	12
Liposomal doxorubicin	23	28

Liposomal doxorubicin/Bevacizumab	3	27
Methotrexate (intravenous)	35	0
Methotrexate/Actinomycin D	4	0
Niraparib	0	0
Olaparib	0	0
Paclitaxel	5	19
Paclitaxel/Bevacizumab	6	4
Pembrolizumab	2	18
Pembrolizumab/Bevacizumab	0	4
Taxotere	4	16
Topotecan	38	64
Topotecan/Bevacizumab	0	7
Paclitaxel, cisplatin/Paclitaxel, etoposide	4	2
Vincristine/Actinomycin/cyclophosphamide	2	0
XELOX (capecitabine and oxaliplatin)	1	3
<b>Total number of courses of chemotherapy</b>	<b>688</b>	<b>1163</b>

# Publication

## Scholarly books, monographs and chapters

Ngan H.Y.S., Chan K.K.L. and Ngu S.F., Gestational trophoblastic disease, In: Sabaratnam Arulkumaran, William Ledger, Lynette Denny, and Stergios Doumouchtsis, *Oxford Textbook of Obstetrics and Gynaecology*. Oxford University Press, 2020, 809-16. <http://dx.doi.org/10.1093/med/9780198766360.003.0066> (Publication Date: Jan 2020)

Ngan H.Y.S. and Chan K.K.L., Gynaecological Oncology, In: Ian Symonds & Sabaratnam Arulkumaran, *Essential Obstetrics and Gynaecology*. Elsevier, 2020. (Publication Date: Jan 2020)

Tse K.Y. and Ip P.C.P., Cervical Cancer Prevention, In: Ho PC et al, *Practical Obstetrics and Gynaecology*. Hong Kong University Press, 2020. (Publication Date: Jan 2020)

## Journal publications

Brotherton J., Davies C., Garland S.M., Stanley M., Moscicki A.B., Giuliano A.R., Brotherton J., Kaufmann A., Bhatla N., Palefsky J., Chan K.K.L. and Woo Y.L., [IPVS policy statement. Equity in cervical cancer prevention: for all and not just for some](#), *Papillomavirus Research*. 2020, 9, 100192. <http://dx.doi.org/10.1016/j.pvr.2019.100192> (Publication Date: Jun 2020)

Chai Y.K.V., Cheung S.Y.C. and Chan K.K.L., [Outcome of vaginal stripping for vaginal intraepithelial neoplasia: A 20-year observational study](#), *Journal of Obstetrics and Gynaecology Research*. 2020. <http://dx.doi.org/10.1111/jog.14482> (Publication Date: Sep 2020)

Chan D.W., Yung M.H., Chan Y.S., [XUAN Y](#), YANG Y., XU D., ZHAN J., Chan K.K.L., NG T.B. and Ngan H.Y.S., [MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis](#), *Pharmacological Research*. 2020,

105157. <http://dx.doi.org/10.1016/j.phrs.2020.105157> (Publication Date: Aug 2020)

Chan K.K.L., Liu S., Wei N., Ngu S.F., Chu M.Y.M., Tse K.Y., Lau S.K., Cheung A.N.Y. and Ngan H.Y.S., [Primary HPV testing with cytology versus cytology alone in cervical screening—A prospective randomized controlled trial with two rounds of screening in a Chinese population](#), *International Journal of Cancer*. 2020. <http://dx.doi.org/10.1002/ijc.32861> (Publication Date: Jan 2020)

Chan K.K.L., Siu K.Y., JIANG Y., WANG J., WANG Y., Leung T.H.Y., Cheung A.N.Y. and Ngan H.Y.S., Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis, *BMC Cancer*. <http://dx.doi.org/10.1186/s12885-017-3601-1> (Date Accepted for Publication: Aug 2017)

Chan K.K.L., Ngu S.F., Chu M.Y.M., Tse K.Y. and Ngan H.Y.S., [Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 -year clinical experience in a tertiary referral center](#), *Asia-Pacific Journal of Clinical Oncology*. 2020. <http://dx.doi.org/10.1111/ajco.13478> (Publication Date: Oct 2020)

Choi P.H., Liao Q., Soong S.I., **Chan K.K.L.**, Lee C.C.Y., Ng A., Sze W.K., Tsang J.W.H., Lee V.H.F. And Lam W.W.T., [Measurement Invariance Across Gender And Age Groups, Validity And Reliability Of The Chinese Version Of The Short-Form Supportive Care Needs Survey Questionnaire \(Scns-Sf34\)](#), *Health And Quality Of Life Outcomes*. 2020, 18. [Http://Dx.Doi.Org/10.1186/S12955-020-01289-0](http://Dx.Doi.Org/10.1186/S12955-020-01289-0)

JIANG Y., Siu K.Y., WANG J., MO X., Leung T.H.Y., Chan D.W., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., [Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer](#), *British Journal of Cancer*. 2020, 123, 275-287. <http://dx.doi.org/10.1038/s41416-020-0865-z> (Publication Date: Jul 2020)

Jiang N., Zhang Q., Chau K.M., Yip M.S., Lui S.L., Liu S., Chu K.M., Ngan H.Y.S., Chan D.T.M. and Yung S.S.Y., [Anti-fibrotic effect of](#)

- [decorin in peritoneal dialysis and PD-associated peritonitis](#), *EBioMedicine*. 2020, 52, 102661. <http://dx.doi.org/10.1016/j.ebiom.2020.102661> (Publication Date: Feb 2020)
- Kwok A.L., Wong G.W., Wong E.S.Y., Tsun O.K.L., Chan K.K.L. and Cheung A.N.Y., Caution over use of ES2 as a model of ovarian clear cell carcinoma , *Journal of Clinical Pathology*. <http://dx.doi.org/10.1136/jclinpath-2014-202430> (Date Accepted for Publication: Jul 2014)
- Kwong A., Shin V.Y., Chen J., Cheuk W.Y.I., Ho C.Y., Au C.H., Chan K.K.L., Ngan H.Y.S., Chan T.L., Ford J.M. and Ma E.S., Germline mutation in 1,338 BRCA-negative Chinese hereditary breast and/or ovarian cancer patients: clinical testing with a multigene test panel, *Journal of Molecular Diagnostics*. 2020, 22, 544-554. <http://dx.doi.org/10.1016/j.jmoldx.2020.01.013> (Publication Date: Apr 2020)
- Kwong A., Cheuk W.Y.I., Shin V.Y., Ho Y.S.C., Au C.H., Ho D.N.Y., Wong E.Y.L., Yu S.W.Y., Chen J., Ngan H.Y.S., Chan T.L. and Ma E.S.K., [Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing](#), *American Journal of Cancer Research*. 2020, 10(9), 2919-2932. (Publication Date: Jul 2020)
- LI X., NG S.N., Mak C.Y., Chan K.K.L., Cheung A.N.Y. and Cheung W.T.L., [Strategic combination therapies for ovarian cancer](#), *Current Cancer Drug Targets*. 2020, 20. <http://dx.doi.org/10.2174/1568009620666200511084007> (Publication Date: May 2020)
- Lee E.Y.P., AN H., Perucho J.A.U., Chiu W.H.K., Hui S.K., Chu M.Y.M. and Ngan H.Y.S., [Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma](#), *European Radiology*. 2020. <http://dx.doi.org/10.1007/s00330-020-06887-6> (Publication Date: May 2020)
- Lee E.Y.P., AN H., Tse K.Y. and Khong P.L., [Molecular Imaging of Peritoneal Carcinomatosis in Ovarian Carcinoma](#), *American Journal of Roentgenology*. 2020, 215, 305-312. <http://dx.doi.org/10.2214/AJR.19.22621> (Publication Date: Jun

2020)

Lee J.H.S., Cheng O.L.E., Choi K.M.C., Ngu S.F. and Cheung R.Y.K., 2020 Hong Kong College of Obstetricians and Gynaecologists guideline on investigations of premenopausal women with abnormal uterine bleeding, *Hong Kong Medical Journal*. 2020, 26(6), 520-525. <http://dx.doi.org/10.12809/hkmj208897> (Publication Date: Dec 2020)

Leung C.O.N., Deng W., Ye T.M., Ngan H.Y.S., Tsao G.S.W., Cheung A.N.Y., Ziru N., Yuen D.C.K., Pang T.K.R. and Yeung W.S.B., MicroRNA-135a-induced formation of CD133+ subpopulation with cancer stem cell properties in cervical cancer, 2020 May 16: bga025, *Carcinogenesis*. 2020, 16. (Publication Date: May 2020)

Leung C.O.N., Deng W., Ye T., Ngan H.Y.S., Tsao G.S.W., Cheung A.N.Y., Niu Z., Yuen D.C.K., Pang T.K.R. and Yeung W.S.B., [MicroRNA-135a-induced formation of CD133+ subpopulation with cancer stem cell properties in cervical cancer](http://dx.doi.org/10.1093/carcin/bga025), *Carcinogenesis*. 2020. <http://dx.doi.org/10.1093/carcin/bga025> (Publication Date: May 2020)

Liu S., Chan K.K.L., Chu K.H., Wei N., Lau S.K., Ngu S.F., Chu M.Y.M., Tse K.Y., Ip P.C.P., Ng K.O., Cheung A.N.Y. and Ngan H.Y.S., Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer, *Molecular Oncology*. (Date Accepted for Publication: Sep 2018)

MO X., Leung T.H.Y., Tang W.M., Siu K.Y., WAN K.T., Chan K.K.L., Cheung A.N.Y. and Ngan H.Y.S., [CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma](http://dx.doi.org/10.1038/s41416-020-0922-7), *British Journal of Cancer*. 2020, 123, 833-843. <http://dx.doi.org/10.1038/s41416-020-0922-7> (Publication Date: Sep 2020)

Ng S.F., Wei N., Li J., Chu M.Y.M., Tse K.Y., Ngan H.Y.S. and Chan K.K.L., Nurse-led follow-up in survivorship care of gynaecological malignancies-A randomised controlled trial, *European Journal of Cancer Care*. 2020. <http://dx.doi.org/10.1111/ecc.13325> (Publication Date: Sep 2020)

Ng S.F. and Ngan H.Y.S., Surgery including fertility-sparing treatment

- of GTD, *Best Pract Res Clin Obstet Gynaecol.*  
2020. <http://dx.doi.org/10.1016/j.bpobgyn.2020.10.005> (Publication Date: Oct 2020)
- Perucho J.A.U., Wang M., Tse K.Y., Ip P.C.P., Siu W.K.S., Ngan H.Y.S., Khong P.L. and Lee E.Y.P., [Association between MRI histogram features and treatment response in locally advanced cervical cancer treated by chemoradiotherapy](http://dx.doi.org/10.1007/s00330-020-07217-6), *European Radiology*.  
2020. <http://dx.doi.org/10.1007/s00330-020-07217-6> (Publication Date: Sep 2020)
- Siu K.Y., JIANG Y., WANG J., Leung T.H.Y., Ngu S.F., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., [PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via  \$\alpha 5\beta 1\$  integrin and JNK/IL-8 signaling](http://dx.doi.org/10.1038/s41389-020-0209-0), *Oncogenesis*.  
2020, 9. <http://dx.doi.org/10.1038/s41389-020-0209-0> (Publication Date: Feb 2020)
- TSOI T.T., Chiu W.H.K., Chu M.Y.M., Ngan H.Y.S. and Lee E.Y.P., [Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers](http://dx.doi.org/10.1186/s13048-020-00662-3), *Journal of Ovarian Research*. 2020, 13, 61. <http://dx.doi.org/10.1186/s13048-020-00662-3> (Publication Date: Dec 2020)
- Tse K.Y. and Chan K.K.L., Recent Advances in the Management of Primary Epithelial Ovarian Cancer, *Journal of Paediatrics Obstetrics and Gynaecology*. 2020, 46, 81-97. (Publication Date: Jun 2020)
- WAN K.T., Siu K.Y., Leung T.H.Y., MO X., Chan K.K.L. and Ngan H.Y.S., [Role of Nurr1 in Carcinogenesis and Tumor Immunology: A State of the Art Review](http://dx.doi.org/10.3390/cancers12103044), *Cancers*. 2020, 12, 3044. <http://dx.doi.org/10.3390/cancers12103044> (Publication Date: Oct 2020)
- Wan Pk, Leung Th, Siu Mk, Mo Xt, Tang Hw, **Chan Kk**, Cheung An, Ngan Hy. Hpv-Induced Nurr1 Promotes Cancer Aggressiveness, Self-Renewal, And Radioresistance Via Erk And Akt Signaling In Cervical Cancer. *Cancer Lett*. 2020 Sep 30;497:14-27. Doi: 10.1016/J.Canlet.2020.09.025. Epub Ahead Of Print. Pmid: 33010383
- WANG J., Siu K.Y., JIANG Y., Leung T.H.Y., Chan D.W., CHENG R., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and



survival through elevation of PD-L1, *OncoImmunology* . <http://dx.doi.org/10.1080/2162402X.2019.1659092> (Date Accepted for Publication: Aug 2019)

WANG J., Siu K.Y., JIANG Y., Chan D.W., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., [Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression](http://dx.doi.org/10.1007/s00262-020-02621-9), *Cancer Immunology, Immunotherapy*. 2020. <http://dx.doi.org/10.1007/s00262-020-02621-9> (Publication Date: Jun 2020)

WANG M., Perucho J.A.U., Tse K.Y., Chu M.Y.M., Ip P.C.P. and Lee E.Y.P., [MRI texture features differentiate clinicopathological characteristics of cervical carcinoma](http://dx.doi.org/10.1007/s00330-020-06913-7), *European Radiology*. 2020. <http://dx.doi.org/10.1007/s00330-020-06913-7> (Publication Date: May 2020)

Wong W.C., Ng J.H.Y., Han K.C., Leung Y.P., Shek C.M., Cheung K.N., Choi C.K.M., Tse K.Y. and Ip P.C.P., [Cervical carcinomas with serous-like papillary and micropapillary components: illustrating the heterogeneity of primary cervical carcinomas](http://dx.doi.org/10.1038/s41379-020-0627-8), In: George J. Netto, *Modern Pathology*. 2020. <http://dx.doi.org/10.1038/s41379-020-0627-8> (Publication Date: Jul 2020)

Yu Y., Tse K.Y., Lee H.Y.H., Chow K.L., Tsang H.W., Wong W.C., Cheung E.T.Y., Cheuk W., Lee V.W.K., Chan W.K., Wong A.S.T., Loong H.H.F., **Chan K.K.L.**, Ngan H.Y.S., Cheung A.N.Y. And Ip P.C.P., Predictive Biomarkers And Tumor Microenvironment In Female Genital Melanomas: A Multi-Institutional Study Of 55 Cases, *Modern Pathology*. 2020 Jan;33(1):138-152, [Http://Dx.Doi.Org/10.1038/S41379-019-0345-2](http://Dx.Doi.Org/10.1038/S41379-019-0345-2) (Publication No. : 301794;)

## Conference papers

JIANG Y., Siu K.Y., WANG J., Leung T.H.Y., Ngu S.F., Chan D.W., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., The upregulation of PFKFB3/PDK4 enhances ovarian cancer stemness properties in tumor progression. , *The 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018)*. (Date Accepted for Publication: Sep 2018)

Kwong A., Au C.H., Ho D.N., Wong E.Y.L., Chung Y., Law F.B.F., Ho Y.S.C., Chen J., Cheuk W.Y.I., Shin V.Y., Chan T.L., Ngan H.Y.S. and Ma E.S.K., [Personalized and cost-effective detection of copy number variants by molecular-barcode next-generation sequencing and long-read nanopore sequencing \(Poster Presentation\)](#), *San Antonio Breast Cancer Symposium, San Antonio, U.S.A., 10-14 December 2019 / Cancer Research*. 2020, Epub on 2020-02-14. <http://dx.doi.org/10.1158/1538-7445.SABCS19-P6-08-13> (Publication Date: Feb 2020)

Lee H.Y.H., Chow K.L., WONG H.S., CHONG T.Y., Tse K.Y., Bray M.A.R.K., Mak T.W. and Ip P.C.P., [Abstract 4130: Improvement of drug efficacy of polo-like kinase 4 inhibitor in the treatment of uterine leiomyosarcoma](#), *Experimental and Molecular Therapeutics*. American Association for Cancer Research, 2020, 4130-4130. <http://dx.doi.org/10.1158/1538-7445.AM2020-4130> (Publication Date: Aug 2020)

Lee H.Y.H., Chow K.L., Wong H.S., Chong T.Y., Tse K.Y. and Ip P.C.P., [Abstracts from USCAP 2020: Gynecologic and Obstetric Pathology \(1142\): Ataxia–Telangiectasia Mutated \(ATM\) Protein Expression in Uterine Smooth Muscle Tumors](#), *Modern Pathology*. Nature, 2020, 33, 1164-1337. <http://dx.doi.org/10.1038/s41379-020-0473-8> (Publication Date: Mar 2020)

Ngu S.F., Yung S.F.S., Li R.H.W., Tse K.Y., Ngan H.Y.S. and Chan K.K.L., A Web-side Teaching Clinic in Obstetrics and Gynaecology during COVID-19 Pandemic, *Frontiers in Medical and Health Sciences Education 2020*. “Medical Education Disrupted – Negativity or Creativity” *Virtual Conference*. 2020. (Publication Date: Nov 2020)

Tse K.Y., Chan K.T., Liu S. and Ngan H.Y.S., Olaparib mediated DNA damage response and its resistant mechanism in cervical cancer cells, *American Association for Cancer Research Virtual meeting*. 2020. <http://dx.doi.org/10.1158/1538-7445.AM2020-2961> (Publication Date: Jun 2020)

WANG H., Ngan H.Y.S. and Chan D.W., Malignant ascites microenvironment skews M2/M1 macrophage polarization in ovarian cancer during peritoneal metastasis, *AACR Annual Meeting 2020*. <http://dx.doi.org/10.1158/1538-7445.AM2020-980> (Date

Accepted for Publication: May 2020; Publication Date: Jun 2020)

XUAN Y., Ngan H.Y.S. and Chan D.W., SCD1/FADS2 and ferroptosis signalings orchestrate ovarian cancer cell metabolism and metastatic progression in peritoneal metastases, *AACR Annual Meeting 2020*. <http://dx.doi.org/10.1158/1538-7445.AM2020-5039> (Date Accepted for Publication: May 2020; Publication Date: Jun 2020)

Yu W.Y.S., Cheuk W.Y.I., Shin V.Y., Ho Y.S.C., Au C.H., Ho D., Wong E., Chen J., Chan K., Ngan H.Y.S., Chan T.L., Ma E. and Kwong A., Somatic mutation profiling in BRCA-negative breast cancer patients, *The Royal College of Surgeons of Edinburgh & The College of Surgeons of Hong Kong Conjoint Virtual Scientific Congress 2020, Hong Kong, 19 September 2020 (Virtual) / Surgical Practice*. 2020, 24 (Suppl 1), 6. (Publication Date: Sep 2020)

## **Editorship, Invited lectures and keynote speeches**

Chan K.K.L., Congress for Management of Ovarian Cancer, *Zai Lab Hong Kong Limited, Guangzhou, China, 15 February*. 《北京康華中西醫結合基金會》, 2020. (Publication Date: Feb 2020)

Chan K.K.L., ISPCM Annual Meeting , *International Society of Precision Cancer Medicine (ISPCM), Tokyo, Japan, 2-4 March 2020*. (Date Accepted for Publication: Mar 2020; Publication Date: Mar 2020)

Chan K.K.L., Review Therapeutic Modalities (Cryo-cautery, LLETZ & Laser) - Colposcopy Workshop Programme, *RCOG Congress, Muscat, Oman, 25-28 March*. 2020. (Publication Date: Mar 2020)

Chan KKL. Salvage surgery for recurrent cervical cancers after primary radiotherapy. Radiotherapy and Oncology Symposium (July 2020)

Chan KKL. Sentinel Node in Endometrial Cancer. HKCOG postgraduate seminar (November 2020)

Chan KKL. Fertility sparing treatment in gynaecological oncology. Hong Kong Sanatorium and Hospital OG symposium (November 2020)

- Ngan H.Y.S., 如何培訓一名婦科腫瘤醫生, *Chinese Gynecologic Cancer Society (CGCS) Annual Meeting, September 25- 17, 2020 [Virtual Meeting]*. 2020. (Publication Date: Sep 2020)
- Ngan H.Y.S., Editorial Advisor, *Journal of Gynecologic Oncology (2018-2020)*. 2020. (Publication Date: Mar 2020)
- Ngan H.Y.S., Editorial Board Member, *Global Gynecology and Obstetrics (GGOB)* . 2020. (Publication Date: Jun 2020)
- Ngan H.Y.S., 卵巢癌的標準治療, *Finding The Balance” China-US Online Academic Conference, September 23, 2020 [Virtual Meeting]*. 2020. (Publication Date: Sep 2020)
- Ngan H.Y.S., GTD: State of the Art Management of High risk, Ultra-High Risk and Recurrent/Refractory Disease , *IGCS Annual Global Meeting, September 12, 2020 [Virtual Meeting]*. 2020. (Publication Date: Sep 2020)
- Ngan H.Y.S., Practical Experience of Niraparib, *East Meets West International Online Conference, (by Webinar), March 17, 2020*. (Publication Date: Mar 2020)
- Ngan H.Y.S., Updates in the management of ovarian cancer, *Macau Obstetricians and Gynaecologists Association Annual Scientific Meeting, November 8, 2020 [Virtual Meeting]*. 2020. (Publication Date: Nov 2020)
- Ngan H.Y.S., Updates on the management of cervical cancer , *Hong Kong Sanatorium & Hospital Symposium: An Update in Gynaecological Oncology, Hong Kong October 18, 2020*. (Date Accepted for Publication: Oct 2020; Publication Date: Oct 2020)
- Ngan H.Y.S., Updates on the management of endometrial cancer, *Endometrial Carcinoma Expert Meeting, Hong Kong, October 30, 2020*. (Publication Date: Oct 2020)
- Ngan H.Y.S., 婦科腫瘤醫生需要了解基因組學和遺傳學嗎?, *廣州中山大學附屬第一醫院 2020 年中歐婦科內鏡高峰論壇(SESIGE), August 27, 2020 [Virtual Meeting]*. 2020. (Publication Date: Aug 2020)
- Ngu S.F., Interactive Case Sharing, *Expanding the Reach of Targeted*

*Therapy for Ovarian Cancer: Clinical Updates and Application in Real-World.* 2020. (Publication Date: Jun 2020)

Tse K.Y., COVID-19 and Gynaecological Cancer Management: Chemotherapy, Targeted Therapy, and Immunotherapy, *sia & Oceania Federation of Obstetrics & Gynaecology (AFOG) Webinar.* (Date Accepted for Publication: Jul 2020)

Tse K.Y., Guest Editor, *Frontiers in Oncology.* (Date Accepted for Publication: Dec 2020)

Tse K.Y., Guest Editor, *Frontiers in Oncology.* (Date Accepted for Publication: Dec 2020)

